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Hepatitis B virus (HBV) is a major cause of liver dis-
ease. Assembly of the HBV capsid is a critical step
in virus production and an attractive target for new
antiviral therapies. We determined the structure of
HBV capsid in complex with AT-130, a member of
the phenylpropenamide family of assembly effec-
tors. AT-130 causes tertiary and quaternary struc-
tural changes but does not disrupt capsid structure.
AT-130 binds a hydrophobic pocket that also ac-
commodates the previously characterized heteroar-
yldihydropyrimidine compounds but favors a unique
quasiequivalent location on the capsid surface.
Thus, this pocket is a promiscuous drug-binding
site and a likely target for different assembly effec-
tors with a broad range of mechanisms of activity.
That AT-130 successfully decreases virus production
by increasing capsid assembly rate without disrupt-
ing capsid structure delineates a paradigm in anti-
viral design, that disrupting reaction timing is a viable
strategy for assembly effectors of HBV and other
viruses.
INTRODUCTION
Current antiviral therapies focus on outright inhibition of viral
processes. For example, entry inhibitors have been developed
to combat human immunodeficiency virus (HIV) by blocking viral
entry into the target cell by inhibiting either host-virus interac-
tions or membrane fusion (Eggink et al., 2010). Protease inhibi-
tors used against HIV block the cleavage steps necessary for
viral maturation (Wensing et al., 2010). A wide variety of nucleo-
side analogs bind viral polymerases in herpes simplex virus, hep-
atitis C virus, HIV, and hepatitis B virus (HBV) to block synthesis
of the viral genomes (Mene´ndez-Arias, 2008; Snoeck, 2000;
Toniutto et al., 2006; Yuen and Lai, 2011). Release inhibitors
have been developed against influenza that block the necessary
host receptor cleavage (Jackson et al., 2011). Due to the muta-
tion-prone nature of virus replication, resistance is always a1406 Structure 21, 1406–1416, August 6, 2013 ª2013 Elsevier Ltd Alserious problem for any antiviral therapy, and new drugs with
newmodes of action are continuously sought (Razonable, 2011).
One underexploited target for antivirals is assembly of the
virus capsid, the protein coat that encloses the viral genome
and any other components necessary to virus structure or func-
tion. The capsid does play a protective role, sequestering the
genomic material from outside threats, but it is not a static shell
(Bothner et al., 1998; Gertsman et al., 2010; Hilmer et al., 2008;
Johnson, 2003; Lewis et al., 1998; Monroe et al., 2010; Phelps
and Post, 1995; Tuma et al., 2008). Rather, it is a dynamic struc-
ture comprised of flexible subunits and is capable of a wide
range of movement and involvement in many cellular processes.
In the case of HBV, upon viral entry, the capsid must expose
nuclear localization signals in order to interact with host traf-
ficking machinery for transport to the nucleus (Yeh et al.,
1990). Upon reaching the nucleus, the capsid must release its
contents to initiate replication (Rabe et al., 2003). Newly synthe-
sized capsid subunitsmust assemble with high fidelity at the cor-
rect time and place and package the correct viral pregenomic
RNA and associated proteins with high specificity (Porterfield
et al., 2010). Initiation of DNA synthesis from the packaged
RNA is dependent on capsid formation and core phosphoryla-
tion state (Lan et al., 1999; Lott et al., 2000). The DNA-containing
virions must then be shuttled through the cell via host export
pathways to the endoplasmic reticulum for secretion or to the
nucleus (Lambert et al., 2007). Once released from the cell, the
capsidmust remain stable in the extracellular milieu until it enters
a new host cell, wherein it must release its genetic material in
order to restart the HBV lifecycle (Ganem and Schneider, 2001).
The ability of the virion to participate in these dynamic pro-
cesses is due in large part to the properties of the capsid protein.
One hundred and twenty copies of the homodimeric capsid pro-
tein (Cp) form a T = 4 icosahedron, the most populous species
found in HBV virions, in which each monomer must adopt one
of four slightly different conformations corresponding to the
quasiequivalent environments dictated by the symmetry of the
icosahedral complex (Wynne et al., 1999; Zlotnick et al., 1997).
Capsid assembly is initiated by the slow formation of a trimer
of Cp dimers to form a nucleus, followed by the rapid step-
wise addition of single dimers to form a complete capsid (Ceres
and Zlotnick, 2002; Zlotnick et al., 1999a). Cp itself is a largely
a helical structure that consists of a central chassis domain
and three distal subdomains—the spike tip, the contact domain,l rights reserved
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Promiscuous Allosteric Pocket in HBV Capsidand the fulcrum helix—linked to the chassis by glycine and pro-
line hinge residues that allow each subdomain to move indepen-
dently (Packianathan et al., 2010). Assembly can be triggered by
an allosteric conformational switch of Cp from an ‘‘open’’ inac-
tive state into the capsid-like assembly-active state (Chen
et al., 2011; Packianathan et al., 2010). Recent studies have
shown a wide range of conformations available to the capsid
dimer and have confirmed that the assembly-active state is
indeed more compact (DiMattia et al., 2013; Tan et al., 2013).
After assembly, the protein must still be flexible enough to allow
exposure of peptide sequences that carry signals for intracellular
trafficking (Bothner et al., 1998; Yeh et al., 1990; Zlotnick et al.,
1997). Cores may then be exported from a cell, gaining an enve-
lope, or transported to the nucleus, a process in common with a
new infection. Nuclear entry requires the virus capsid to undergo
further conformational change, destabilization, and/or disas-
sembly to release its genome (Rabe et al., 2003). All of these
processes are dynamic and must be tightly regulated.
Contrary to the examples of viral enzyme inhibitors described
above, studies in HBV assembly have shown that the opposite
effect, activation of virus assembly, is a very effective antiviral
measure (Zlotnick and Stray, 2003). The heteroaryldihydropyri-
midine (HAP) compounds, originally identified by Bayer, were
found to be nonnucleoside assembly activators that increase
the pairwise contacts between the capsid subunits, driving
assembly further and faster to the point of misdirecting assem-
bly into large, pleiomorphic noncapsid structures (Stray et al.,
2005; Stray and Zlotnick, 2006;Weber et al., 2002). In cell culture
and animal models, HAP treatment leads to the clearance of the
capsid protein from the cell and does not produce intact virus
(Deres et al., 2003; Weber et al., 2002). Determination of the
5 A˚ resolution crystal structure of the HBV capsid in complex
with a prototypical member of the HAP family, HAP1, resulted
in a cautious assignment of theHAP1-binding site to a hydropho-
bic pocket at the dimer-dimer interface (Bourne et al., 2006).
HAP1 binding did not alter the protein shape or block its ability
to self-assemble; in fact, it causes a stronger interdimer contact
energy. However, HAP binding also changed the geometry of the
contacts between capsid protein dimers at the quaternary level,
resulting in an overall disruption of the spherical capsid structure
and (at high stoichiometry of HAP to capsid protein) resulting in
misassembly (Bourne et al., 2008). The low-resolution assign-
ment of the HAP1 site has been tested with a HAP-resistant
capsid protein mutant. The insertion of a tryptophan residue
that partially fills the binding pocket confers HAP-like activities
upon the resulting protein: assembly was faster, subunit-subunit
interactions were stronger, the mutation inhibited viral DNA syn-
thesis when expressed in culture, andmutant Cp had a dominant
negative phenotype when coexpressed with wild-type HBV Cp
(Tan et al., 2013).
Another class of nonnucleoside compounds, the phenylpro-
penamides, also had anti-HBV activity in cell culture (Delaney
et al., 2002; King et al., 1998; Perni et al., 2000). Studies with
these compounds suggested that the phenylpropenamides
appeared to block RNApackaging, producing apparently normal
capsids that lacked genetic material (Feld et al., 2007). Subse-
quent studies revealed an assembly effector mechanism under-
lying the apparent blocking of RNA packaging (Katen et al.,
2010). The effects of the phenylpropenamides are almost entirelyStructure 21, 1406kinetic, affecting only assembly reaction rate and timing while
still producing normal capsids, with very little thermodynamic
effects on capsid stability. The loss of RNA packaging is not
the direct result of these compounds but presumably a second-
ary consequence of initiating assembly without viral RNA (Katen
et al., 2010).
Given that the effectiveness of the HAP compounds correlates
directly with their effects on assembly rate, rather than their
thermodynamic aspects (Bourne et al., 2008), and the fact that,
despite different chemistries, the HAPs and phenylpropena-
mides have similar size and hydrophobicity, we proposed that
phenylpropenamides might act on HBV assembly in the same
way and in the same site as the HAPs, with the observed differ-
ences in behavior arising from the weaker effect on capsid stabil-
ity of the phenylpropenamides (Katen et al., 2010). To explore
this hypothesis, we have now solved a 4.2 A˚ structure of the
HBV Cp assembly domain in complex with AT-130 (Protein
Data Bank Code 4G93). AT-130 is the phenylpropenamide deriv-
ative with the greatest reported efficacy in cell culture (EC50 =
0.13 mM; Perni et al., 2000). We discovered that, while AT-130
does bind the same hydrophobic pocket as HAP, the pockets
of the different quasiequivalent subunits within the capsid asym-
metric unit are not identical, and AT-130 favors a different
quasiequivalent location than the one favored by HAP1. While
there are some quaternary changes that were similar to those
observed with HAP1, the phenylpropenamides also induced
compensatory tertiary structural changes (not observed with
the HAPs) that likely allow the formation of the observed normal
capsids rather than the noncapsid polymers observedwith HAPs
(Tan et al., 2013). This structure identifies a promiscuous binding
pocket as a highly attractive target for multiple antivirals and
reveals that relatively modest effects on the molecular level
can still correlate with significant antiviral effects.
RESULTS
Cocrystallization with AT-130 Altered Crystal Packing
and Capsid Morphology
The crystallization properties, crystal packing, and unit cell
dimensions of HBV capsids crystallized in the presence of AT-
130 (hereafter, the +AT-130 structure) were markedly different
from those of the analogous apo (lacking drug) structure (Protein
Data Bank Code 2G33). The +AT-130 unit cell dimensions were
similar to those of the structure of the HBV capsid cocrystallized
with HAP1 (Protein Data Bank [PDB] code 2G34) (Table 1;
Table S1 and Figure S1 available online; Bourne et al., 2006).
Phenylpropenamide-bound HBV capsids retained their T = 4
morphology with two quasiequivalent dimers in the asymmetric
unit (Figure 1A); previous studies showed that coassembly with
AT-130 still yielded what appeared to be normal capsids (Fig-
ure 1B), so we had expected that they would be compatible
with T = 4 symmetry (Feld et al., 2007; Katen et al., 2010). How-
ever, global differences between the apo and drug-bound struc-
ture were readily apparent. Superposition of the density of the
two structures (Figures 1C and S2) showed that the drug-bound
capsid was swollen compared to the native form. The inner sur-
face of the superimposed capsids is dominated by the native
structure, while the outer surface is dominated by the greater
diameter of the drug-bound structure. The diameter difference–1416, August 6, 2013 ª2013 Elsevier Ltd All rights reserved 1407
Table 1. Data Collection and Refinement Statistics
Parameter
HBV 3CA Cp150 + AT-130
Valuea
X-ray source APS 14-BMC
Space group C2
Unit Cell Constants
a = 527.4 A˚
b = 362.8 A˚
c = 538.2 A˚
a = g = 90, b = 105.1
Resolution (A˚) 40.0–4.20 (4.27–4.20)b
Rsym 0.123 (0.882)
Average I /s 10.2 (1.1)
Completeness 99.1 (97.5)
Redundancy 3.0 (2.9)
No. of unique reflections 700,096 (34,333)
60-Fold NCS Averaging
R factor 0.24
Correlation coefficient 0.941
Torsion Dynamics and Positional Refinement
Number of atomsc 4,542
rmsd bond length (A˚) 0.005
rmsd bond angle () 1.00
Ramachandran preferred,
disallowed (%)
64.32, 12.43
R factord 0.37
Mean Atomic Temperature Factor, B (A˚2)
Protein 59.8
AT-130 57.1
See also Table S1.
aHighest resolution shell statistics in parentheses.
bThere are visible reflections to 3.9 A˚, but the large number of weak reflec-
tions results in a high R factor and a low I/s. Imposing a 4.2 A˚ cutoff
results in an I/s of 1.1 in the highest resolution shell, and 60-fold NCS
averaging allows these data to make an observable contribution to
density.
cNumber of atoms in the icosahedral asymmetric unit.
dDue to the 60-fold NCS averaging, theR free value is correlated with and
identical to the R factor, so is not reported here.
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Promiscuous Allosteric Pocket in HBV Capsidwas most prominent around the 5-fold axes. From the density
superposition of capsid viewed at the A/B dimer, which forms
the 5-fold vertex, it was evident that the increase in capsid diam-
eter resulted from an elevation of the entire dimer with respect to
that of the apo capsid (Figure S2A). From spike tip to spike tip
around the 5-fold axis, there is an approximately 8 A˚ increase
in capsid diameter due to the 5-fold bulging. In contrast, the
density superposition of the C/D dimer showed no consistent
elevation (Figure S2B).
AT-130 Binding Causes Differential Quaternary and
Tertiary Changes in the Quasiequivalent Subunits
Detailed comparison of dimers extracted from the highest avail-
able resolution (3.3 A˚) native (apo) capsid (PDB code 1QGT;
Wynne et al., 1999) with the refined +AT-130 structure was per-1408 Structure 21, 1406–1416, August 6, 2013 ª2013 Elsevier Ltd Alformed to identify structural changes due to AT-130 binding. The
global comparisons obscured tertiary structural differences. The
root-mean-square deviation (rmsd) for the C-alphas of the +AT-
130 noncrystallographic asymmetric unit (the A/B and C/D dimer
complex, which is repeated 60 times to form a T = 4 icosahedron)
compared to the 1QGT noncrystallographic asymmetric unit was
0.9 A˚, indicating that the overall structures of the subunits were
maintained. When the two individual dimers within the noncrys-
tallographic asymmetric unit were overlaid independently, the
rmsd for the A/B dimer was only 0.8 A˚. From a plot of the dis-
placements of the C-alphas of the +AT-130 A/B subunits
compared to those of the apo structure, it was apparent that
there was no region of distinct difference (Figure 2A). In contrast,
while the overall rmsd for the C/D dimers was slightly elevated
at 1.0 A˚, a minimal overall difference, a plot of C-alpha dis-
placements (Figure 2B) showed a significant number of individ-
ual atoms had shifted by more than 2.0 A˚, indicating regions
where there were systematic changes in the capsid protein
structure.
In the context of an HBV capsid, there are multiple levels of
quaternary structure: an A/B dimer, a C/D dimer, the two-dimer
icosahedral asymmetric unit, and the complete capsid. The
change in A/B structure is almost entirely due to changes in
capsid quaternary structure. Examining the overlay of the A/B
dimers from the apo and +AT-130 structures in the context of
the capsid, it is clear that, though the tertiary structures of the
individual monomers were essentially unchanged (Figure 2A), it
is readily apparent that they are spatially out of register (Fig-
ure 3B). AT-130 binding induces an upward motion of the A/B
dimer as a rigid body (Figures 3A and S2A). The entire dimer
pivots as a rigid body, with residue Y132 of the B-chain, which
is deeply buried in the interdimer interface, as the apparent
fulcrum (Figure S3B). The upward displacement is minimal at
the extreme of the B-chain, because this was near the center
of the pivot, but the entire subunit is elevated from this point,
resulting in a full 4.0 A˚ upward displacement at the opposite
end of the dimer. This is also readily apparent in the upward shift
of the A-monomer spike tip and assembly domain (Movie S1).
This pivoting motion of the A/B dimer is the basis of the bulging
at the 5-fold axes seen in the completed capsid.
In contrast to the radial shifting observed with HAP1 (Bourne
et al., 2006), the +AT-130 structure shows no apparent pivoting
or sidewaysmotion of the C/D dimer. The overlaid densities have
no vertical mismatch, and the helices within the structure are
largely in register (Figures 3C and 3D). However, the density
overlay reveals divergence between the two structures in the
upper region of the spike (Figure S2B). The plot of displacement
of subunit C-alphas compared to the native structure shows a
sharp increase in displacement of the atoms of the spike tip (Fig-
ures 2C, 3C, and 3D), particularly in the upper region of the
descending spike helix. The upper portion of the spike is delin-
eated by two conserved glycines located in the middle of the
ascending and descending helices at positions 63 and 94,
respectively (Figure S3B). These glycines, atypical residues for
an a helix, have been proposed to serve as a hinge between
the upper portion of the spike and the central chassis region
of the protein, facilitating movement of the spike as an inde-
pendent subdomain within the capsid protein (Packianathan
et al., 2010).l rights reserved
Figure 1. Capsid Structure in the Presence
of AT-130
(A) A hepatitis B capsid structure showing qua-
siequivalence and asymmetric unit. The A/B dimer
(red and blue respective monomers) forms icosa-
hedral 5-fold, while the C/D dimer (yellow and
green respective monomers) forms icosahedral
3-fold. Color scheme is maintained for remaining
figures.
(B) Electron micrograph of Cp149 assembly with
AT-130 showing morphologically normal 35 nm
capsids.
(C) +AT-130 crystal structure (red) overlaid with
apo structure (blue) showing drug-induced capsid
expansion. Left: exterior of overlaid structures.
Right: cross-section of overlaid structures. Icosa-
hedral symmetry axes are indicated.
See also Figure S2.
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Promiscuous Allosteric Pocket in HBV CapsidExamination of the +AT-130 structure reveals a significant
tertiary change in the upper spike regions of the C/D dimer as
delineated by these two glycines (Movie S2). In the C-monomer,
the lower portion of ascending helix is very closely aligned with
the native structure (Figure 3C). However, the region of the
ascending helices above glycine 63 ‘‘drifts’’ from the native
structure, tilting toward the D subunit. As the chain progresses
upward, it loses its a helical character (i.e., hydrogen bonding
and fc angles) a full turn before that of the native structure
and does not return to an a helix for a full two turns below
the equivalent helix in the apo structure. It appears that the
entire spike tip has unraveled and splayed outward. Approach-
ing the second glycine hinge in the descending helix, there is
a visible kink in the helix that displaces the C-alpha backbone
by 4.5 A˚. Beyond glycine 94, the structures are again in close
alignment. While the overall rmsd for the C-monomer is only
0.9 A˚, the rmsd for the upper portion of the spike (residues
69–93) is 1.7 A˚.
In the D-monomer, the entire ascending helix appears to be
skewed. The base of the helix is slightly tilted to the right (orien-
tations with respect to Figure 3) of the native structure, yet
remains closely aligned with the native structure up until the
hinge glycine 63. Above that, it slants to the left of the native
helix so that the upper portion of the spike is similar to the
C-monomer. The tilting makes the helices appear out of register
with the apo structure (Figures 3D and S2B). The ascending
helix of the D-monomer completes the same number of turnsStructure 21, 1406–1416, August 6, 2013 ªas the native structure, but after the
loop at the tip of the spike, the descend-
ing helix begins a complete turn later
than in the apo structure; the spike
tip of the D-monomer is unraveled to a
lesser extent than in the C-monomer.
However, with a substantial kink at
glycine at position 94, the upper portion
of the D descending helix is even more
severely displaced than in the C-mono-
mer, displacing the C-alpha backbone
by a full 5.0 A˚ (Figures 2B and 3D). The
rmsd for the D-monomer as a wholeis 1.1 A˚, but for the upper spike region (residues 69–93;
Figure S3B), the rmsd is 2.3 A˚.
Definition of the AT-130 Binding Site
The binding sites of AT-130 were identified by electron density
(particularly evident in the sharpened map) that could not be
attributed to protein. In a hydrophobic pocket located at the con-
tact between B and C dimers, the same pocket where the HAP
compounds were proposed to bind (Figures 4 and S3B), density
of comparable detail to that of the protein chains was visible. It
was strongest in the pocket of the B-monomer, visible above
3s (Figures 4B and S4A). While still clear and comparable in
strength to that of the protein, the density in the pocket of the
C-monomer was somewhat weaker; only a small mass of density
was still visible at a 3s cutoff in the sharpened density map (Fig-
ures 4C and S4B). No density was visible in the pockets of the A-
or D-monomer. This suggests that AT-130 binds to both B and C
pockets but favors that of the B-monomer; in the C-monomer,
the weaker density may correspond to only partial occupancy.
This implies relatively weak binding of phenylpropenamide com-
pounds to C-sites despite crystallization conditions where there
were two AT-130 molecules for every Cp dimer, implying that
AT-130 binds the C-site with a dissociation constant on the order
of 300 mM.
The observed density in our crystal structure is of sufficient
resolution to confirm that the cis isomer is the form of AT-130
that binds to the HBV capsid protein (Figures 4B, S4A, S4C,2013 Elsevier Ltd All rights reserved 1409
Figure 2. C-alpha Displacement of Overlaid Dimeric Subunits
(A) Displacement of the C-alphas in the A/B dimer from residues 1–139,
showing regions of tertiary structural change. Dimers from the +AT-130
structure were overlaid on the equivalent dimers from 1QGT (Wynne et al.,
1999) to minimize the rmsd of the dimer. Purple bars at the top and bottom of
the panel indicate helical regions (as labeled in Figure S3).
(B) Displacement of the C-alphas in the C/D dimer, overlaid and displayed as
described above.
See also Figure S3.
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Promiscuous Allosteric Pocket in HBV Capsidand S4D). The stronger density in the B-pocket is unambiguous,
and even the weaker density in the C-pocket, when observed at
lower contour, can be identified as the cis isomer of AT-130 (Fig-
ures 4C and S4B). Note that, in a typical phenylpropenamide
sample, the (Z)-olefin isomer (cis isomer) makes up 70%–90%
of the total mass (Figure S4C; King et al., 1998; Perni et al.,1410 Structure 21, 1406–1416, August 6, 2013 ª2013 Elsevier Ltd Al2000; Wang et al., 2011); this is known to be the active form of
the compound with an EC50 of 1.2 mM, compared to over
100 mM for the trans isomer (Figure S4D; Wang et al., 2011).
The relatively narrow hydrophobic pocket cannot accommodate
the bulkier trans isomer, whereas the cis isomer fills the pocket
neatly (Figures S4A–S4D).
Despite having entirely different structures and substantially
different effects on assembly, AT-130 and HAP1 share the
same binding pocket, indicating that this binding site is promis-
cuous and able to accommodate multiple structures (Figure 4A).
However, AT-130 favored a different quasiequivalent site than
HAP1 (Figures 4B and S4A). The HAP1-bound structure showed
significant extra density in the pocket of the C-monomer, and
while there was additional density present in the B-pocket, it
was much weaker (Bourne et al., 2006). The observed behavior
of AT-130 was the opposite: the strongest observable density
attributed to the compound was in the B-pocket, and while
weaker, the additional density in the C-pocket was still as strong
as that of the protein density.
A HAP-Resistant Mutant Confirms the
Phenylpropenamide Binding Site
The phenylpropenamide and HAP binding site is an interfacial
hydrophobic pocket. A mutant capsid protein was constructed,
V124W (Figure 5A), that partially fills the pocket, resulting in
resistance to HAPs (Figure 5B; Tan et al., 2013). Tryptophan
occupies about half the volume of HAP1 or AT-130. Further-
more, the Cp149-V124W mutant is assembly hyperactive,
consistent with a filled HAP site. HAP-12, the most effective
of the previously tested HAP compounds (Bourne et al.,
2008), had negligible effect on Cp149-V124W assembly (Tan
et al., 2013).
To test the assignment of the putative AT-130 density, we
examined the effect of AT-130 on Cp149-V124W assembly.
We used 90 light scattering to examine the effect of AT-130
on Cp149-V124W assembly kinetics. Wild-type protein showed
increased assembly in the presence of AT-130 (Figure 5C; Katen
et al., 2010), whereas Cp149-V124W showed no significant
change in assembly rate or extent (Figure 5D). The valine-to-
tryptophan mutation nullified the effects of AT-130.
DISCUSSION
AT-130 binds in the same putative location as the HAP com-
pounds, which correlates with its properties as an assembly
effector. In the context of a monomer, this pocket is located at
the juncture of all four Cp subdomains (Figure S3). The binding
of the hydrophobic phenylpropenamides molecule could serve
as molecular ‘‘glue,’’ bringing the surrounding flexible subdo-
mains and the central chassis into a more compact, assembly-
active state (Packianathan et al., 2010). Indeed, filling this pocket
with a tryptophan in the V124Wmutant leads to a more compact
dimer, observed by size exclusion chromatography (Tan et al.,
2013). This structure more readily forms the nucleation com-
plex needed to initiate assembly (Zlotnick et al., 1999a). The
kinetic trapping of incomplete intermediates observed with
the related phenylpropenamide B-21 (Figure S4E) supports the
conclusion that nucleation is the affected step of assembly
(Katen et al., 2010).l rights reserved
Figure 3. Tertiary andQuaternary Structural
Changes in the HBV Capsid upon AT-130
Binding
(A) An A/B dimer superposition showing 4.0 A˚
upwardmovement as a rigid body. All structures in
the figure are overlaid in the context of the
complete +AT-130 and 1QGT capsids; the apo
structure is shown in gray, +AT-130 in color.
(B) A 90 rotation of the A/B dimer more clearly
shows the out-of-register alignment of the spike
helices.
(C) C-monomer superposition showing unraveling
and displacement of the spike. Ascending and
descending helices marked with arrows.
(D) D-monomer superposition showing skewing of
the ascending helix and kink in the descending
helix. Ascending and descending helices marked
as in (C).
See also Movies S1 and S2
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Promiscuous Allosteric Pocket in HBV CapsidThe hydrophobic pocket was put forward as the binding site
for the HAP compounds based on a 5 A˚ resolution structure.
Our higher resolution structure enabled us to see the density
with sufficient detail to confirm this binding site and the pub-
lished biochemical data identifying the phenylpropenamide cis
isomer as the active form. Our model of AT-130 in its site is
consistent with phenylpropenamide structure-activity relation-
ship studies (Wang et al., 2011). Substitutions on the piperidine
ring abolished activity (Wang et al., 2011); in our structure, we
observe that this ring is buried in the pocket so that additions
would likely abrogate binding. The o position of the A ring and
p position of the B ring are oriented toward the capsid interior
and exterior, respectively, and the phenylpropenamides are
tolerant of additions and substitutions to these positions. The
other positions of the ring structures are buried within the hydro-
phobic interior, and the loss of activity observed with substitu-
tions at these positions suggest a loss of binding due to a poor
fit within the binding site (Wang et al., 2011). Lastly, the HAP-
resistant V124W mutant, which partially occludes the binding
pocket with a tryptophan residue, is also resistant to AT-130.
These results lead us to confirm that this site is a promiscuous
binding pocket and can accommodate multiple compounds,
including both the HAPs and the phenylpropenamides.
Given the same binding site and their similar accelerating and
stabilizing effects on assembly in vivo, we had expected that the
HAPs and phenylpropenamides would have the same effect on
capsid structure: quaternary shifting of the capsid dimers as rigid
bodies. With AT-130, the A/B dimer quaternary structure change
is very similar to what was observed with HAP1. With the HAPs,
this shift can result in misassembly of the capsid protein into
noncapsid polymers; however, AT-130 supports formation of
morphologically normal capsids. The structural basis of this dif-
ference was evident in the C/D dimers, which, unlike with the
rigid body movement seen with the HAPs (Bourne et al., 2006),Structure 21, 1406–1416, August 6, 2013 ªhad altered tertiary structure. The C/D
intradimer interface was distorted, the
spike-tip broadening and splaying out-
ward to the point of unwinding the spike
helix at the uppermost residues.The observed combination of quaternary and tertiary struc-
tural changes led us to propose a mechanism by which AT-
130-bound capsids maintain their structural integrity where
HAP-bound capsids do not. When AT-130 is bound, the pro-
tein-protein interactions around 5-fold are destabilized (as
HAPs also do [Bourne et al., 2006]), but the C/D dimers adjust
their conformation to accommodate the altered quaternary inter-
actions, holding the A/B dimers in place. This has the observed
effect of retaining the icosahedral quaternary geometry, elimi-
nating the tendency to adopt misdirected aggregate structures
(Figures 6A and 6B). The tertiary structure change of the C/D
dimer may be a compromise to fit the bulk of the phenylpropena-
mide (compared to a relatively planar HAP) and still assemble a
T = 4 capsid. The cost of distorting the C/D dimer would be paid
by the global capsid stability. Conversely, the HAPmolecules do
not impose C/D distortion and consequently lead to aberrant,
noncapsid polymers. We note that HAPs stabilize protein-pro-
tein interaction in HBV much more than phenylpropenamides.
We suggest that the phenylpropenamides pay a thermodynamic
price for distorting the four helix bundles that makes their
enhancement of capsid stability weaker than seen with the
HAPs, which cause no such tertiary distortion.
Subtle conformational shifts in capsid subunits are reminis-
cent of molecular motions that have been proposed to be
responsible for signal transduction in the infectious virion. Spe-
cifically, motion around the spike tip upon DNA synthesis and
capsid maturation and also exposure of the C terminus from
the capsid exterior may be structural signals for virus secretion
(Bo¨ttcher et al., 1998; Chen et al., 2011; Ning et al., 2011; Rose-
man et al., 2005; Wang et al., 2012a). Image reconstructions of
HBV capsids with inserts in the spikes have revealed an addi-
tional degree of flexibility within dimers of the assembled capsid
(Bo¨ttcher et al., 2006). Thus, all current evidence points to the
HBV capsid being a highly dynamic molecule that undergoes2013 Elsevier Ltd All rights reserved 1411
Figure 4. AT-130 Binding in the Promiscuous
Pocket at the Base of the Dimer
(A) AT-130 cis isomer (purple) and HAP1 (cyan)
molecular models shown overlapping in the AT-130
density in the C-subunit, the preferred location for
HAP1 (Bourne et al., 2006). The AT-130 density
(purple) is contoured at 1.5s (Figures S4C and S4D).
(B) AT-130 density is strongest at the base of the
B-subunit (Figure S4A).
(C) Weaker but clearly visible AT-130 density in the
equivalent pocket in C.
(D) An overview of AT-130 binding sites. AT-130 binds
in both the B/C quasiequivalent binding pocket (site 1)
and the C/D pocket (site 2) but favors site 1.
See also Figure S4 and Movie S3.
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Promiscuous Allosteric Pocket in HBV Capsidstructural changes as necessary steps in the virus lifecycle but
without disrupting the overall capsid geometry.
Changes in conformation are clearly transmitted across the
entire structure. AT-130 was shown to bind only in the hydropho-
bic pockets of the B- and C-monomers, and yet the A-monomer
showed the greatest vertical displacement, while the D-mono-
mer spike had the largest rmsd from the native structure. Small
local changes communicated across the capsid protein are
the basis of the argument for the role of allostery in viral assem-
bly, signaling, and disassembly (Bo¨ttcher et al., 2006; Tang et al.,
2006). Thus, the structure presented here demonstrates an
important implication of the high degree of plasticity of the
HBV capsid: quaternary changes are compensated for by
tertiary structural changes to maintain capsid integrity. The plas-
ticity we observe suggests that the HBV capsid (and capsids of
other viruses) accommodate a broad continuum of asymmetric
motion and conformations. While we observe icosahedrally
ordered structural changes, the high degree of conformational
plasticity suggests a freedom that may break icosahedral sym-
metry (Wang et al., 2012b).
AT-130 and HAP1 show different quasiequivalent binding
preferences. In the +HAP1 capsid structure, the strongest HAP
density was located in the pocket of the C-subunit (Bourne
et al., 2006). In the +AT-130 structure, the strongest density
was in the B-subunit pocket, indicating a binding preference
there. It seems that the breakdown of HBV quasiequivalence
extends to the binding pockets. An HBV capsid has 60 copies
each of four unique binding pockets. This raises the possibility
of designing antiviral compounds that target different quasiequi-
valent sites for maximal disruption of assembly. In fact, this has
already been observed to some degree; low concentrations of1412 Structure 21, 1406–1416, August 6, 2013 ª2013 Elsevier Ltd All rights reservedAT-130 and BAY41-4109 (HAP1) synergisti-
cally reduced virus production (Billioud
et al., 2011). However, antagonism exists
between the two compounds at higher con-
centrations. Our structure reveals that, while
AT-130 does prefer the B-pocket, it can also
bind in the C-position and vice versa for
HAP1. It is possible that the high concentra-
tion antagonism stems from competition
between the two compounds. Examination
of the effects of both these molecules
together on HBV capsid assembly mayshed further light on the synergy and antagonism between
different binding pockets. The observed effects may arise solely
from competition for the same site, or filling one site may affect
binding to the other. Thus, both compounds in concert may
also change the thermodynamic and kinetic assembly properties
of the capsid in ways different from the compounds alone.
The lifecycle of any virus is an exquisitely timed and regulated
process; a focused disruption can be devastating to virus repli-
cation. The greater implication is that a molecule does not
need to induce large structural changes or possess inhibitory
properties in order to function as a successful antiviral. Phenyl-
propenamides are effective antiviral compounds, even though
they have relatively subtle effects on capsid structure and
assembly, decreasing virus production to levels comparable
with the superior members of the HAP family (Figure S5). Virion
assembly initiated at the wrong point in time, which is what the
phenylpropenamides appear to do, results in morphologically
normal capsids that are empty and noninfectious (Figure 6C;
Feld et al., 2007). While most antiviral therapies tend to focus
on inhibition or termination of a viral process, we propose that
deregulation or mistiming of a viral process is an equally viable
strategy for the design of antiviral compounds. Potential antiviral
targets have been overlooked because their effects on virus
replication were not classically inhibitory.
The HBV capsid protein and its assembly process have no
human analogs, making HBV assembly a very attractive target
for new antiviral therapies. We have determined the binding site
of a representative of a second family of assembly effectors, a
member of the phenylpropenamide family, AT-130, and in
doing so have shown that the HAP-binding pocket is promiscu-
ous and can be considered a target for a wide variety of small
Figure 5. HAP-Resistant Capsid Protein
Mutant Is Insensitive to AT-130
(A) A valine residue (yellow sticks/spheres) makes
up part of the assigned AT-130 (purple sticks/
spheres) binding site.
(B) The V124W mutation (green sticks/spheres)
partially occludes the proposed binding site for
AT-130.
(C) Light scattering (in arbitrary units) of Cp149
assembly in 150 mM NaCl with AT-130.
(D) Light scattering of Cp149-V124W assembly in
50 mM NaCl with AT-130.
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Promiscuous Allosteric Pocket in HBV Capsidmolecules. Our results demonstrate that the quasiequivalent
nature of the capsid results in four subtly different targets.
The capsid can accommodate a great range of motion and ter-
tiary and quaternary conformational change while still maintain-
ing its structural integrity. However, even small changes can
significantly alter the assembly properties of the virus and
significantly disrupt the normal lifecycle. That the modest
effects of AT-130 can have such a significant decrease in virus
production illustrates an alternative paradigm for antiviral com-
pounds; while inhibitors of viral processes (e.g., nucleoside
analogs) are potent antiviral compounds, ‘‘deregulators’’ of
the viral processes may be equally effective antiviral therapies.
This approach offers opportunities for effective combination
therapies.
EXPERIMENTAL PROCEDURES
Sample Preparation
Cp149 capsid protein dimer from hepatitis B subtype adyw was expressed in
E. coli and purified as described previously (Zlotnick et al., 2002). The V124W
mutant was purified using a modified protocol (Tan et al., 2013). Frozen
aliquots of Cp were dialyzed against assembly buffer (50 mM HEPES,
pH 7.5) prior to light scattering experiments. For crystallization, a Cp149
mutant, 3CA-Cp150, was used, wherein three native cysteine residues were
mutated to alanine and an additional cysteine was appended at position 150
(Bourne et al., 2006). T = 4 3CA-Cp150 capsids were purified from free dimer
and T = 3 particles by sucrose gradient sedimentation as described previously
and immediately dialyzed for crystallization (Zlotnick et al., 1999b). The phenyl-
propenamide compound AT-130 was synthesized as described previously
(Katen et al., 2010).
Light Scattering
Observation of kinetics by 90 light scattering was observed with a Photon
Technology International fluorometer set to 400 nm for both excitation and
emission (Katen et al., 2010). Light scattering was measured for 10 mM (final
concentration) wild-type Cp149 reduced with 5% b-mercaptoethanol
(Packianathan et al., 2010; Tan et al., 2013). Assembly was induced by addi-Structure 21, 1406–1416, August 6, 2013 ªtion of NaCl to a final concentration of 150 mM
NaCl, with and without the addition of 20 mM
AT-130. The V124W assembly experiment fol-
lowed the same procedure, with the exception
that assembly was initiated with 50 mM NaCl,
due to the mutant assembly hyperactivity (Tan
et al., 2013).
Electron Microscopy
Samples from light scattering experiments were
adsorbed to glow-discharged carbon over paralo-
dian copper grids (EM Sciences). Samples were
stained with 2% uranyl acetate and visualizedwith a JEOL 1010 transmission electron microscope equipped with a 4K 3
4K Gatan charge-coupled device camera.
Crystallization
Crystallization was optimized from previously determined conditions for the
adyw 3CA-Cp150 capsid (Bourne et al., 2006). Cocrystals were grown in the
presence of half-molar, equimolar, and 2-fold excess molar concentration of
AT-130 in DMSO (relative to the concentration of Cp in capsid form). Crystal-
lization was carried out at room temperature with 4 ml sitting drops, initiated by
a 1:1 mixture of protein solution with well solution. Protein solutions contained
10 mg/ml 3CA Cp150 capsid in 5 mM Tris buffer, pH 7.5, 150 mM NaCl, and
0.7%–3% DMSO. Well solutions were composed of 5%–10% polyethylene
glycol 5000 monomethylether, 0%–5% polyethylene glycol 8000 monomethy-
lether, 6%–28% 2,3-butanediol, 100 mM Tris pH 9.0, 150 mM NaCl, and
300 mM KCl.
Diffraction Data Collection
Crystals were cryoprotected as described previously (Bourne et al., 2006).
Crystals were flash-frozen in a stream of gaseous 170C nitrogen before
transport to the Advanced Photon Source (APS) Beamline 14BMC for data
collection. The final data set was collected from a single cryocooled crystal
containing a 2:1 molar ratio of AT-130 to Cp dimer; statistics are in Table 1.
Structure Solution and Refinement
Molecular replacement and averaging was used for phasing. The native adw-
like capsid structure (PDB code 1QGT) was used as the phasing model
(Wynne et al., 1999). Molecular replacement was carried out with the Phaser
program in the CCP4 program suite (Collaborative Computational Project,
Number 4, 1994; McCoy et al., 2007). Phases calculated to 7 A˚ were
subjected to 60-fold noncrystallographic symmetry (NCS) averaging and
phase extension using the RAVE suite (Kleywegt et al., 2001). NCS aver-
aging produced an averaging R factor of 26.0% and a correlation coefficient
of 93.7%.
Refinement was carried out with CNS (Bru¨nger et al., 1998) using strict
icosahedral NCS, isotropic B-factor correction, and bulk solvent scaling. AT-
130 refinement was carried out through positional refinement in conjunction
with torsionmolecular dynamics, with slow-cooling from 2,000 K in 50 K steps.
Further refinement was iterated with 60-fold NCS averaging and manual
rebuilding in Coot (Emsley et al., 2010). A test set of 5,000 reflections was2013 Elsevier Ltd All rights reserved 1413
Figure 6. Model of AT-130 as a Kinetic Effector of HBV Assembly through Subtle Conformational Changes
(A) Schematic of HBV capsid structure showing the arrangement of the asymmetric unit on an icosahedral face.
(B) Model of allosteric changewith AT-130 binding; the quaternary upwardmotion of the A/B dimers is compensated for by tertiary conformational changes within
the C/D dimers.
(C) Proposed AT-130 mechanism of action. Normal virus assembly involves the packaging of the reverse transcriptase pregenomic RNA (RT-pgRNA) complex
(Nassal, 2008); AT-130 binds to the capsid protein and induces subtle conformational changes that cause the formation of nuclei without the RT-pgRNA complex,
leading to the formation of empty particles.
See also Figure S5.
Structure
Promiscuous Allosteric Pocket in HBV Capsidfor Rfree cross-validation, but the resulting Rfree was virtually identical to the
crystallographic R factor, due to NCS correlation of the test and working
data sets. The molecular model was refined to yield a crystallographic R factor
of 37% (Table 1), a value consistent with those of other heavily averaged
structures at comparable resolutions.
Superpositions of models were carried out in Coot (Emsley et al., 2010).
Figures were generated with PyMol (DeLano, 2009) and Chimera (Pettersen
et al., 2004).
ACCESSION NUMBERS
The atomic coordinates and structure factors have been deposited in
the RCSB Protein Data Bank (http://www.rcsb.org/pdb) with the accession
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